###begin article-title 0
Activation of Interleukin-32 Pro-Inflammatory Pathway in Response to Influenza A Virus Infection
###end article-title 0
###begin p 1
Conceived and designed the experiments: YZ WL JW. Performed the experiments: WL YL SR YG GP YC. Analyzed the data: WL YL JW. Contributed reagents/materials/analysis tools: MM RG YP SR LK QH XC. Wrote the paper: YZ WL.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 222 227 <span type="species:ncbi:9606">human</span>
Interleukin (IL)-32 is a recently described pro-inflammatory cytokine that has been reported to be induced by bacteria treatment in culture cells. Little is known about IL-32 production by exogenous pathogens infection in human individuals.
###end p 3
###begin title 4
Methods and Findings
###end title 4
###begin p 5
###xml 609 610 609 610 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 106 114 <span type="species:ncbi:9606">patients</span>
###xml 127 144 <span type="species:ncbi:11320">influenza A virus</span>
###xml 331 348 <span type="species:ncbi:11320">influenza A virus</span>
###xml 363 368 <span type="species:ncbi:9606">human</span>
In this study, we found that IL-32 level was increased by 58.2% in the serum samples from a cohort of 108 patients infected by influenza A virus comparing to that of 115 healthy individuals. Another pro-inflammatory factor cyclooxygenase (COX)-2-associated prostaglandin E2 was also upregulated by 2.7-fold. Expression of IL-32 in influenza A virus infected A549 human lung epithelial cells was blocked by either selective COX-2 inhibitor NS398 or Aspirin, a known anti-inflammatory drug, indicating IL-32 was induced through COX-2 in the inflammatory cascade. Interestingly, we found that COX-2-associate PGE2 production activated by influenza virus infection was significantly suppressed by over-expression of IL-32 but increased by IL-32-specific siRNA, suggesting there was a feedback mechanism between IL-32 and COX-2.
###end p 5
###begin title 6
Conclusions
###end title 6
###begin p 7
###xml 20 37 <span type="species:ncbi:11320">influenza A virus</span>
IL-32 is induced by influenza A virus infection via COX-2 in the inflammatory cascade. Our results provide that IL-32 is a potential target for anti-inflammatory medicine screening.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 523 526 523 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Heitmeier1">[1]</xref>
###xml 528 531 528 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Jacobs1">[2]</xref>
###xml 695 698 695 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Jacobs1">[2]</xref>
###xml 825 828 825 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Guillot1">[3]</xref>
###xml 830 833 830 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Ciencewicki1">[4]</xref>
###xml 920 923 920 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Steer1">[5]</xref>
###xml 925 928 925 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Steer2">[6]</xref>
###xml 930 933 930 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Traynor1">[7]</xref>
###xml 1093 1096 1093 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Heitmeier1">[1]</xref>
###xml 1098 1101 1098 1101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Eliopoulos1">[8]</xref>
###xml 1103 1106 1103 1106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Maggi1">[9]</xref>
###xml 1108 1112 1108 1112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Nath1">[10]</xref>
###xml 0 17 <span type="species:ncbi:11320">Influenza A virus</span>
###xml 19 21 <span type="species:ncbi:11320">IV</span>
###xml 132 138 <span type="species:ncbi:9606">humans</span>
###xml 797 814 <span type="species:ncbi:11320">influenza A virus</span>
Influenza A virus (IV) is a highly contagious single-stranded RNA virus that infects both the upper and lower respiratory tracts of humans. The host innate immune Toll-like receptor 3 (TLR3) was shown previously in cells of myeloid origin to recognize the viral replicative, intermediate double-stranded RNA (dsRNA). Thus, dsRNA is critical for the outcome of the infection and appears to be an active component of viral infection that stimulates antiviral activities. It accumulates during the replication of many viruses [1], [2], including influenza virus. Prominent sources of dsRNA include viral RNAs containing double-stranded secondary structure and dsRNA formed during viral replication [2]. Furthermore, TLR3 contributes directly to the immune response of respiratory epithelial cells to influenza A virus and dsRNA [3], [4]. Therefore dsRNA treatment was always used to mimic the viral infection in cell lines [5], [6], [7]. In macrophages, dsRNA and viral infection stimulate the expression of pro-inflammatory cytokines such as IL-1alpha, IL-1beta, tumor necrosis factor, and IL-6 [1], [8], [9], [10].
###end p 9
###begin p 10
###xml 336 340 336 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Hinz1">[11]</xref>
###xml 451 455 451 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Marnett1">[12]</xref>
###xml 635 639 635 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Deng1">[13]</xref>
###xml 641 645 641 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Iniguez1">[14]</xref>
###xml 798 802 798 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Liu1">[15]</xref>
###xml 804 808 804 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Yan1">[16]</xref>
###xml 825 826 825 826 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 831 832 831 832 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 857 858 857 858 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1060 1063 1060 1063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Steer1">[5]</xref>
###xml 1065 1068 1065 1068 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Steer2">[6]</xref>
###xml 1070 1074 1070 1074 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Carey1">[17]</xref>
###xml 1076 1080 1076 1080 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Gilroy1">[18]</xref>
Cyclooxygenase (COX) is the rate-limiting enzyme in the biosynthetic pathway of prostaglandins and thromboxanes. Prostaglandins play an important role in many biological processes. Altered prostanoid production is associated with a variety of illnesses, including acute and chronic inflammation, cardiovascular disease and colon cancer [11]. Two isoforms of COX were described: COX-1 and COX-2. COX-1 is constitutively expressed in almost all tissues [12]; COX-2 is the inducible form of the enzyme, which is expressed in response to inflammatory stimuli and growth factors and is involved in mediating pain and inflammatory processes [13], [14]. In our previous studies, we identified two viral proteins, the nucleoprotein and spike protein of SARS-CoV, which were involved in up-regulating COX-2 [15], [16]. Prostaglandin E2 (PGE2) is synthesized from PGH2 in a variety of cells, which itself is synthesized from arachidonic acid by the enzyme prostaglandin synthetase COX-2. Its levels can be measured to access the COX-2 activity as described in reference [5], [6], [17], [18].
###end p 10
###begin p 11
###xml 397 401 390 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Kim1">[19]</xref>
###xml 580 584 573 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Kundu1">[20]</xref>
###xml 662 666 655 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Joosten1">[21]</xref>
###xml 688 714 681 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Mycobacterium tuberculosis</italic>
###xml 714 718 707 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Netea1">[22]</xref>
###xml 835 839 825 829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Netea2">[23]</xref>
###xml 975 979 961 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Novick1">[24]</xref>
###xml 306 312 <span type="species:ncbi:10090">murine</span>
###xml 379 384 <span type="species:ncbi:9606">human</span>
###xml 688 714 <span type="species:ncbi:1773">Mycobacterium tuberculosis</span>
Interleukin-32 (IL-32), previously called natural killer cell transcript 4, has been recognized as a pro-inflammatory cytokine recently. It is mainly expressed in natural killer cells, T cells, epithelial cells and blood monocytes. IL-32 can induce the pro-inflammatory cytokines TNF-alpha and IL-1beta in murine peritoneal macrophages as well as in phorbol ester-differentiated human THP-1 cells [19]. It plays an important role in innate and adaptive immune responses, synergism between IL-32 and other well-characterized players in innate immunity has recently been documented [20]. Furthermore, IL-32 contributes to the synovitis during rheumatoid arthritis [21]. It is stimulated by Mycobacterium tuberculosis[22] and it synergizes with NOD1 and NOD2 ligands to stimulate IL-1beta and IL-6 release in a caspase-1-dependent manner [23]. Recently Proteinase 3 has been identified as a specific IL-32alpha binding protein which cleaves the cytokine to enhance its activity [24].
###end p 11
###begin p 12
###xml 105 106 105 106 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 120 123 120 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Steer2">[6]</xref>
###xml 125 129 125 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Liu1">[15]</xref>
###xml 131 135 131 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Yan1">[16]</xref>
###xml 137 141 137 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-LaraPezzi1">[25]</xref>
###xml 143 147 143 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Mizumura1">[26]</xref>
###xml 170 187 <span type="species:ncbi:11320">influenza A virus</span>
A number of investigations demonstrated that viral infections stimulate COX-2 expression, followed by PGE2 accumulation [6], [15], [16], [25], [26]. However, the role of influenza A virus infection in the regulation of the newly described pro-inflammatory factor IL-32 expression is still unclear. Furthermore, since COX-2 and IL-32 are obligatory mediators of inflammation, the question arises as to whether there is an interaction between the two proteins or they act as independent effectors of host inflammatory response to viral infection.
###end p 12
###begin p 13
###xml 136 153 <span type="species:ncbi:11320">influenza A virus</span>
###xml 281 298 <span type="species:ncbi:11320">influenza A virus</span>
###xml 417 434 <span type="species:ncbi:11320">influenza A virus</span>
Because COX-2 and IL-32 gene expression are associated with inflammatory processes, the aim of this study is to investigate the role of influenza A virus infection in the regulation of IL-32 expression and to determine the molecular mechanisms responsible. Our results showed that influenza A virus infection or poly(IC) treatment activates COX-2 and IL-32 expression by a heretofore unrecognized mechanism, in which influenza A virus stimulates IL-32 expression through COX-2, and IL-32 feedback inhibits COX-2 expression.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 15
###begin p 16
###xml 47 64 <span type="species:ncbi:11320">influenza A virus</span>
###xml 301 318 <span type="species:ncbi:10407">hepatitis B virus</span>
###xml 320 323 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 326 343 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 345 348 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 378 381 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 573 581 <span type="species:ncbi:9606">patients</span>
###xml 777 782 <span type="species:ncbi:9606">human</span>
The study examined 108 consecutive adults with influenza A virus infection (59 male, 49 female, aged 39.2+/-13.5 yr) seropositive for influenza A antigen and 115 healthy adults (62 male, 53 female, aged 37.6+/-11.3 yr) seronegative for influenza A antigen. All adults were seronegative for markers of hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis Delta virus, and HIV. All of the investigated serum samples were obtained with the help from Hubei provincial Center for Disease Control and Prevention (Hubei CDC). Informed consent was obtained from each of the patients. The collection of blood samples for research was approved by the Institutional Review Board of the College of Life Sciences, Wuhan University in accordance with guidelines for the protection of human subjects.
###end p 16
###begin title 17
Virus
###end title 17
###begin p 18
###xml 29 36 <span type="species:ncbi:9031">chicken</span>
###xml 197 204 <span type="species:ncbi:9031">chicken</span>
The influenza virus strain A/chicken/Hubei/327/2004 (H5N1) used in this study was provided by China Center for Type Culture Collection (CCTCC). Stock virus was propagated in 10-day-old embryonated chicken eggs for 36 to 48 h at 37degreesC. The allantoic fluid was then harvested, and aliquots were stored at -80degreesC before being used. The final concentration of H5N1 virus infection used in this study was 1 multiplicity of infection (MOI).
###end p 18
###begin title 19
Plasmids, antibodies, and inhibitors
###end title 19
###begin p 20
###xml 222 226 222 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Zhu1">[27]</xref>
###xml 328 363 328 363 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GTTACGCGTCCTATTTCAATATGACTGGT-3&#8242;</named-content>
###xml 373 410 373 410 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- GTTAAGCTTAGGGAAAGTCCAGACTCGGG -3&#8242;</named-content>
###xml 757 791 757 791 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- CATGAATTCCATGTGCTTCCCGAAGG -3&#8242;</named-content>
###xml 801 839 801 839 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- CTACTCGAGGTATCTTCATTTTGAGGATTG -3&#8242;</named-content>
###xml 862 865 862 865 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Eco</italic>
###xml 872 875 872 875 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Xho</italic>
###xml 946 949 946 949 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Eco</italic>
###xml 956 959 956 959 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Xho</italic>
###xml 273 278 <span type="species:ncbi:9606">human</span>
###xml 632 637 <span type="species:ncbi:9606">human</span>
pcDNA3.1-COX-2 was a gift from Dr. Kenneth K. Wu (University of Texas-Houston Medical School, Houston, Texas, USA). Luciferase reporter vector (pGL3) containing a COX-2 promoter region (-891/+9) was constructed previously [27]. IL-32 promoter (-746/+25) was amplified from human genomic DNA by PCR, using the following primers: 5'-GTTACGCGTCCTATTTCAATATGACTGGT-3' (sense), 5'- GTTAAGCTTAGGGAAAGTCCAGACTCGGG -3' (antisense); and then inserted into pGL3-Basic vector to generate IL-32 promoter and Luciferase gene fusion plasmid (pIL-32-Luc). An IL-32 construct was created by RT-PCR amplification of the open reading frame from A549 human lung epithelial cells. To create IL-32-encoding vector, the IL-32 beta gene was amplified using the following primers: 5'- CATGAATTCCATGTGCTTCCCGAAGG -3' (sense), 5'- CTACTCGAGGTATCTTCATTTTGAGGATTG -3' (antisense); in which EcoRI and XhoI sites were introduced, respectively. The PCR product was cloned into EcoRI and XhoI sites of pCMV-tag2A (Stratagene) to generate plasmid Flag2A-IL-32, in which IL-32 beta protein was tagged by FLAG.
###end p 20
###begin p 21
###xml 375 411 375 411 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- ACGGGATCCGATGGAGAAAATAGTGCTT -3&#8242;</named-content>
###xml 421 454 421 454 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- ACGCTCGAGTGAACTCACAAATTTA -3&#8242;</named-content>
###xml 524 562 524 562 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- AAAGGGCCCCTACTTGTCAATGGTGAATGG -3&#8242;</named-content>
###xml 580 616 580 616 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- AAAGGATCCCATGGCGTCTCAAGGCACC -3&#8242;</named-content>
###xml 626 659 626 659 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- ACCGAATTCTTAATTGTCATACTCC -3&#8242;</named-content>
###xml 678 716 678 716 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- ACAGGATCCGATGGATTCCAACACTGTGTC -3&#8242;</named-content>
###xml 726 759 726 759 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- CTTGAATTCTCAGCCACCTTATTTC -3&#8242;</named-content>
###xml 778 816 778 816 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- ACAGGATCCGATGGATTCCAACACTGTGTC -3&#8242;</named-content>
###xml 826 865 826 865 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- CTAGGGCCCATCATTAAATAAGCTGAAACGA -3&#8242;</named-content>
###xml 883 915 883 915 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- TCTGAATTCGATGAGTCTTCTAAC -3&#8242;</named-content>
###xml 925 962 925 962 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- TTAGGGCCCGCAACAACAAGAGGATCACT -3&#8242;</named-content>
###xml 980 1012 980 1012 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- TCTGAATTCGATGAGTCTTCTAAC -3&#8242;</named-content>
###xml 1022 1058 1022 1058 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- TTTCTCGAGGGTAGTTTTTTACTCCAAT -3&#8242;</named-content>
###xml 1076 1113 1076 1113 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- AATGGATCCTATGGAAGACTTTGTGCGAC -3&#8242;</named-content>
###xml 1123 1160 1123 1160 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- CAGGGGCCCTACTTCAGTGCATGTGCGAG -3&#8242;</named-content>
###xml 1179 1216 1179 1216 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- CAAACGGATCCCATGGATGTCAATCCGAC -3&#8242;</named-content>
###xml 1226 1263 1226 1263 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- CAAGAAGCTTTCACTATTTCTGCCGTCTG -3&#8242;</named-content>
###xml 1282 1310 1282 1310 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- GCAAAAGCAGGTCAAATATA -3&#8242;</named-content>
###xml 1320 1350 1320 1350 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- GTTTTTAAACAATTCGACACTA -3&#8242;</named-content>
###xml 1459 1477 1459 1468 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Silencer&#8482;</italic>
###xml 1566 1570 1557 1561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Shoda1">[28]</xref>
###xml 24 41 <span type="species:ncbi:11320">influenza A virus</span>
###xml 153 155 <span type="species:ncbi:11320">IV</span>
###xml 336 353 <span type="species:ncbi:11320">influenza A virus</span>
All of the ten genes of influenza A virus H5N1 were obtained by RT-PCR from H5N1 infected A549 cells and constructed into pCMV-Flag2A vector to generate IV-gene expressing plasmids (Flag2A-HA, Flag2A-NA, Flag2A-NP, Flag2A-NS1 Flag2A-NS2, Flag2A-M1, Flag2A-M2, Flag2A-PA, Flag2A-PB1, Flag2A-PB2) using specific pairs of primers for each influenza A virus gene as follows: HA: 5'- ACGGGATCCGATGGAGAAAATAGTGCTT -3' (sense), 5'- ACGCTCGAGTGAACTCACAAATTTA -3' (antisense); NA: 5'-GCGGAATTCTATGAATCCAAATCAGAAGATAATAAC-3' (sense), 5'- AAAGGGCCCCTACTTGTCAATGGTGAATGG -3' (antisense); NP: 5'- AAAGGATCCCATGGCGTCTCAAGGCACC -3' (sense), 5'- ACCGAATTCTTAATTGTCATACTCC -3' (antisense); NS1: 5'- ACAGGATCCGATGGATTCCAACACTGTGTC -3' (sense), 5'- CTTGAATTCTCAGCCACCTTATTTC -3' (antisense); NS2: 5'- ACAGGATCCGATGGATTCCAACACTGTGTC -3' (sense), 5'- CTAGGGCCCATCATTAAATAAGCTGAAACGA -3' (antisense); M1: 5'- TCTGAATTCGATGAGTCTTCTAAC -3' (sense), 5'- TTAGGGCCCGCAACAACAAGAGGATCACT -3' (antisense); M2: 5'- TCTGAATTCGATGAGTCTTCTAAC -3' (sense), 5'- TTTCTCGAGGGTAGTTTTTTACTCCAAT -3' (antisense); PA: 5'- AATGGATCCTATGGAAGACTTTGTGCGAC -3' (sense), 5'- CAGGGGCCCTACTTCAGTGCATGTGCGAG -3' (antisense); PB1: 5'- CAAACGGATCCCATGGATGTCAATCCGAC -3' (sense), 5'- CAAGAAGCTTTCACTATTTCTGCCGTCTG -3' (antisense); PB2; 5'- GCAAAAGCAGGTCAAATATA -3' (sense), 5'- GTTTTTAAACAATTCGACACTA -3' (antisense); IL-32 siRNA plasmid was constructed by ligating the corresponding pairs of oligonucleotide to pSilencertrade mark 2.1-U6 neo (Ambion, Inc., Augstin, TX, USA) based on the sequences described previously [28]. All constructs was confirmed by DNA sequencing.
###end p 21
###begin p 22
###xml 11 16 <span type="species:ncbi:10090">mouse</span>
###xml 34 39 <span type="species:ncbi:9606">human</span>
###xml 122 126 <span type="species:ncbi:9925">goat</span>
###xml 144 149 <span type="species:ncbi:9606">human</span>
###xml 209 213 <span type="species:ncbi:9925">goat</span>
###xml 236 241 <span type="species:ncbi:9606">human</span>
Monoclonal mouse antibody against human COX-2 was purchased from Cayman Chemical Company (Ann Arbor, MI, USA). Polyclonal goat antibody against human IL-32 was purchased from R&D Systems, Inc. USA. Polyclonal goat antibody specific for human beta-actin (SC-1616) were purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, CA, USA).
###end p 22
###begin p 23
###xml 167 171 167 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Copeland1">[29]</xref>
###xml 306 311 <span type="species:ncbi:9606">human</span>
N-(2-cyclohexylosy-4-nitrophenyl)-methanesulphonamide (NS398) (Promega, Madison, WI) was dissolved in DMSO and used as indicated concentrations according to reference [29]. Aspirin (Sigma, St. Louis, MO, USA), Synthetic polyinosinic-polycytidylic acid poly(IC) (Sigma, St. Louis, MO, USA), and recombinant human interferon-gamma (IFN-gamma) (Peprotech, London, UK) were dissolved in PBS and used at a final concentration of 5 mM, 50 microg/ml, 150 U/ml, respectively.
###end p 23
###begin title 24
Cell culture
###end title 24
###begin p 25
###xml 322 323 312 313 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 54 59 <span type="species:ncbi:9606">human</span>
###xml 189 193 <span type="species:ncbi:9913">calf</span>
HEK 293T cells were cultured in DMEM (GibcoBRL, USA), human lung epithelial cells A549 were cultured in F12K media (GibcoBRL, USA), respectively. All media were supplemented with 10% fetal calf serum, 100 U/ml penicillin and 100 microg/ml streptomycin sulfate and all cell cultures were maintained at 37degreesC in a 5% CO2 incubator.
###end p 25
###begin title 26
Transient transfection and Luciferase reporter gene assays
###end title 26
###begin p 27
###xml 38 39 38 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 758 762 754 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Liu1">[15]</xref>
Cells were plated at density of 4.0x105 cells per 24-well plate or 6-well plate and grown to confluence reaching about 80% at the time of transfection. The plasmids which express COX-2, IL-32, the pGL3-promoter plasmids, pRL-TK (Promega) were co-transfected into the cells by using Lipofectamine 2000 reagent (Invitrogen). If necessary, poly(IC), IFN-gamma, NS398, and Aspirin were added into the culture media after transfection. 24 h post-transfection, cells were serum-starved for another 24 h before being harvested. Luciferase activities were measured 48 h after transfection according to the manufacturer's instructions (Promega) and Renilla Luciferase activities were determined as internal control for transfection efficiency as previously described [15]. Assays were performed in triplicate and expressed as means+/-s.d. relative to vector or mock control as 100 (RLU) or luciferase activity (LUC).
###end p 27
###begin title 28
Semiquantitative RT-PCR analysis
###end title 28
###begin p 29
###xml 317 350 313 346 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- CATGAATTCCATGTGCTTCCCGAAGG-3&#8242;</named-content>
###xml 369 407 365 403 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- CTACTCGAGGTATCTTCATTTTGAGGATTG -3&#8242;</named-content>
###xml 479 483 472 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Liu1">[15]</xref>
###xml 625 630 <span type="species:ncbi:9606">human</span>
Total RNA, isolated from A549 cells using Trizol reagent (Invitrogen, Carlsbad, CA, USA), was treated with DNase I and reverse-transcribed with MLV reverse transcriptase (Promega) and random primers (Takara). PCR was performed in 25 microl reactions with the detection primer pairs described as follows: IL-32 sense: 5'- CATGAATTCCATGTGCTTCCCGAAGG-3'; IL-32 antisense: 5'- CTACTCGAGGTATCTTCATTTTGAGGATTG -3'. Detection primers for COX-2, and beta-actin were described previously [15]. beta-actin was amplified by PCR for normalization in all reactions. The primers for IL-32 were designed for detecting all known isoforms of human IL-32. PCR products were analyzed by electrophoresis on 1% agarose gel containing ethidium bromide.
###end p 29
###begin title 30
Western blot analysis
###end title 30
###begin p 31
Protein extracts of cultured cells were prepared by suspending cells in lysis buffer (0.01% EDTA, 0.1% Triton X-100, 10% proteinase inhibitors cocktail), sonication, and centrifugation. Concentrations of proteins in supernatant were quantified using protein assay kit (Bio-Rad). Western blot analysis was performed using COX-2 and IL-32 antibodies and sample loading was normalized by using beta-actin antibody. Immunoblots were visualized with the ECL detection system (Pierce, Rockford, IL, USA).
###end p 31
###begin title 32
COX-2 activity
###end title 32
###begin p 33
###xml 21 22 21 22 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 105 106 105 106 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Because increased PGE2 is the metabolite of COX-2 enzyme catalysis in epithelial cells, COX-2-derived PGE2 levels in the culture medium was assayed by the Biotrak Prostaglandin E2 Enzyme Immunoassay system (R & D Systems) according to the manufacturer's protocol.
###end p 33
###begin title 34
ELISA for IL-32 measurement
###end title 34
###begin p 35
ELISA assays were developed using IL-32 antibody and a polypeptide, H-KEELTPQKCSEPQSSK-OH, (GL Biochem Ltd. Shanghai China) was synthesized as an antigen for making an IL-32 protein standard curve. ELISAs were prepared by coating the bottom of a 96-well plate with diluted serum samples or culture media. 50 microl of 2 microg/ml capture antibody was incubated for one hour then washed three times with TBST, followed by HRP-labeled secondary antibody incubation for 15 minutes, and finally washed six times with TBST. ELISAs were developed with TMB (Sigma) substrate and the absorbance at double-wavelength 450 nm/630 nm was measured. IL-32 concentrations were calculated from the standard curve.
###end p 35
###begin title 36
Statistical analysis
###end title 36
###begin p 37
###xml 258 259 256 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 400 401 398 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
All experiments were reproducible and were carried out in triplicate or quadruplicate. Each set of experiments was repeated at least three times with similar results, and a representative one is shown. The results are presented at the means+/-s.d. Student's t test for paired samples was used to determine statistical significance. Differences were considered statistically significant at a value of P</=0.05.
###end p 37
###begin title 38
Results
###end title 38
###begin title 39
###xml 19 20 19 20 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Serum levels of PGE2 and IL-32
###end title 39
###begin p 40
###xml 23 24 23 24 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 199 200 197 198 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 301 302 291 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 340 347 330 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0001985-t001">Table 1</xref>
###xml 78 86 <span type="species:ncbi:9606">patients</span>
###xml 92 109 <span type="species:ncbi:11320">influenza A virus</span>
The serum levels of PGE2 and IL-32 were significantly higher in the cohort of patients with influenza A virus infection investigated in comparison with healthy control individuals (mean+/-SEM for PGE2, 808.7+/-52.9 vs. 299.5+/-45.4 pg/ml; for IL-32, 183.8+/-43.6 vs. 116.2+/-29.3 pg/ml, respectively, P<0.01 Mann Whitney-U) as described in Table 1.
###end p 40
###begin title 41
###xml 61 62 61 62 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 99 107 <span type="species:ncbi:9606">patients</span>
Demographic and baseline characteristics, serum levels of PGE2 and IL-32 from influenza A positive patients and healthy individuals.
###end title 41
###begin title 42
###xml 42 59 <span type="species:ncbi:11320">influenza A virus</span>
COX-2 and IL-32 activation in response to influenza A virus infection and dsRNA treatment in a time-dependent manner
###end title 42
###begin p 43
###xml 103 107 103 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Mizumura1">[26]</xref>
###xml 174 175 174 175 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 184 187 184 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Steer1">[5]</xref>
###xml 705 706 701 702 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 721 728 717 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001985-g001">Fig. 1A</xref>
###xml 752 759 748 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001985-g001">Fig. 1B</xref>
###xml 815 836 811 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">materials and methods</xref>
###xml 865 872 861 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001985-g001">Fig. 1C</xref>
###xml 887 894 883 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001985-g001">Fig. 1D</xref>
###xml 224 241 <span type="species:ncbi:11320">influenza A virus</span>
###xml 353 370 <span type="species:ncbi:11320">influenza A virus</span>
###xml 1047 1064 <span type="species:ncbi:11320">influenza A virus</span>
It has been reported that influenza virus can activate the expression of COX-2 in cell culture systems [26] and that dsRNA can induce the production of COX-2, followed by PGE2 release [5]. Initially, we investigated whether influenza A virus infection and dsRNA plays a role, if any, in the regulation of IL-32 expression. A549 cells were infected with influenza A virus or treated with poly(IC)+IFN-gamma, results showed that A549 cells were susceptible to influenza virus infection and apparent cytopathic effect was observed after viral infection. The culture supernatants and cell lysates were harvested at different time points after infection or induction as follows: 0 h, 6 h, 12 h, 24 h, 48 h. PGE2 accumulation (Fig. 1A) and IL-32 production (Fig. 1B) in culture supernatants were measured as described in materials and methods section. COX-2, IL-32 mRNA (Fig. 1C) and protein (Fig. 1D) expression levels in lysated cells were examined by semiquantitative RT-PCR and western blot analyses, respectively. These results suggested that both influenza A virus infection and dsRNA treatment could activate the expression of COX-2 and IL-32 in A549 cells in a time-dependent manner.
###end p 43
###begin title 44
###xml 37 42 <span type="species:ncbi:9606">human</span>
###xml 80 97 <span type="species:ncbi:11320">influenza A virus</span>
COX-2 and IL-32 were induced in A549 human lung epithelial cells in response to influenza A virus infection or dsRNA treatment in a time-dependent manner.
###end title 44
###begin p 45
###xml 21 22 21 22 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 109 126 <span type="species:ncbi:11320">influenza A virus</span>
###xml 517 534 <span type="species:ncbi:11320">influenza A virus</span>
Time-dependent of PGE2 (A) and IL-32 (B) accumulations in A549 culture supernatants are shown in response to influenza A virus infection (1 MOI) or poly(IC) (50 microg/ml)+IFN-gamma (150 U/ml) treatment. Data are expressed as mean+/-s.d. of three independent experiments. Time-dependent of COX-2 and IL-32 mRNA accumulations (C) in cell lysates are shown by Semiquantitative RT-PCR analysis and protein productions (D) shown by western blot analysis, in which A549 cells were harvested at indicated time points after influenza A virus infection (1 MOI) or 48 h treatment with poly(IC) (50 microg/ml)+IFN-gamma (150 U/ml). The gel or blot is a representative of three experiments with similar results.
###end p 45
###begin title 46
###xml 51 68 <span type="species:ncbi:11320">influenza A virus</span>
Identification of the viral components involved in influenza A virus-stimulated COX-2 and IL-32 expression
###end title 46
###begin p 47
###xml 428 435 424 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001985-g002">Fig. 2A</xref>
###xml 447 454 443 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001985-g002">Fig. 2B</xref>
###xml 63 65 <span type="species:ncbi:11320">IV</span>
###xml 544 546 <span type="species:ncbi:11320">IV</span>
###xml 687 689 <span type="species:ncbi:11320">IV</span>
To identify the viral components which play important roles in IV-stimulated pro-inflammatory factors COX-2 and IL-32 expression, we screened all ten proteins of influenza virus: HA, NA, NP, NS1, NS2, M1, M2, PA, PB1, PB2 and poly(IC) (to mimic viral replicative intermediate dsRNA) by luciferase assays. Results showed that poly(IC), poly(IC)+IFN-gamma, and NS1 are the most important factors in the induction of either COX-2 (Fig. 2A) or IL-32 (Fig. 2B) promoter activities, which means dsRNA and NS1 are the key viral components involved in IV-triggered COX-2 and IL-32 expression during viral infection. In this study, we focused on the function of dsRNA in inflammatory response to IV infection.
###end p 47
###begin title 48
Screening of viral proteins or viral replicative intermediate dsRNA involved in induction of COX-2/ IL-32.
###end title 48
###begin p 49
###xml 483 490 471 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">methods</xref>
Reporter plasmids pCOX-2-Luc (A), pIL-32-Luc (B), and pRL-TK were cotransfected along with all 10 viral gene constructs (Flag2A-HA, Flag2A-NA, Flag2A-NP, Flag2A-NS1, Flag2A-NS2, Flag2A-M1, Flag2A-M2, Flag2A-PA, Flag2A-PB1, Flag2A-PB2) and control vectors (Flag2A) or treated with or without poly(IC) (50 microg/ml), poly(IC) (50 microg/ml)+IFN-gamma (150 U/ml) into A549 cells which are indicated on the horizontal axis respectively. Luciferase activity was measured as described in methods section. Results are expressed as the mean+/-s.d. of three independent experiments performed in triplicate and normalized by Renilla activities.
###end p 49
###begin title 50
DsRNA stimulates IL-32 through COX-2 pathway during inflammatory response
###end title 50
###begin p 51
###xml 232 236 228 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-LeGoffic1">[30]</xref>
###xml 49 66 <span type="species:ncbi:11320">influenza A virus</span>
###xml 157 174 <span type="species:ncbi:11320">influenza A virus</span>
To define the role of COX-2 in the regulation of influenza A virus induced pro-inflammatory factor IL-32, poly(IC)+IFN-gamma treatment was used to mimic the influenza A virus infection in following experiments as reported previously[30].
###end p 51
###begin p 52
###xml 231 238 231 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001985-g003">Fig. 3A</xref>
First, the effects of COX-2 on the activation of IL-32 promoter were determined. A549 cells were cotransfected with the reporter plasmid pIL-32-Luc and pcDNA3.1, pcDNA3.1-COX-2 plus different concentration of NS398 as mentioned in Fig. 3A, pcDNA3.1 was used as empty vector control. Results from Luciferase activity assay showed that the level of IL-32 promoter activity was increased by COX-2 over-expression and it was blocked by COX-2 inhibitor NS398 in a dose-dependent manner.
###end p 52
###begin title 53
DsRNA induces IL-32 is in COX-2-dependent manner.
###end title 53
###begin p 54
Reporter plasmid pIL-32-Luc (A), and pRL-TK were cotransfected along with pcDNA3.1-COX-2 or pcDNA3.1 into A549 cells. Transfected cells by COX-2 plasmids were incubated for 12 h and then maintained for 36 h with different final concentrations of NS398 as indicated, respectively. Luciferase activity was measured. Results are expressed as the mean+/-s.d. of three independent experiments performed in triplicate and normalized by Renilla activities. A549 cells were transfected with different indicated amounts of pcDNA3.1-COX-2 or pcDNA3.1. RT-PCR for IL-32 and beta-actin (internal control) (B) in cell lysates, Elisa for IL-32 (C) in culture supernatants were performed. (D) A549 cells were treated with poly(IC) (50 microg/ml)+IFN-gamma (150 U/ml) for 12 h and then different concentration of NS398 was added as indicated for another 36 h. IL-32 and beta-actin mRNA level were examined by RT-PCR. (E) A549 cells were stimulated by poly(IC) (50 microg/ml)+IFN-gamma (150 U/ml) with or without 80 microM NS398 for 48 h. Time-dependent of IL-32 expression in culture supernatants were measured. The data represent mean+/-s.d. of three separate experiments.
###end p 54
###begin p 55
###xml 408 415 402 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001985-g003">Fig. 3B</xref>
###xml 540 547 534 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001985-g003">Fig. 3C</xref>
Secondly, to determine the effects of COX-2 on the activation of IL-32 mRNA level and protein expression, A549 cells were transfected with different amounts of pcDNA3.1-COX-2. Results from RT-PCR using IL-32-specific, or beta-actin-specific primers showed that the levels of IL-32 mRNA were increased as the amount of pcDNA3.1-COX-2 increased, but the levels of beta-actin mRNA remained relatively constant (Fig. 3B). Furthermore, IL-32 production in culture supernatants was stimulated by COX-2 over-expression in a dose-dependent manner (Fig. 3C).
###end p 55
###begin p 56
###xml 183 190 179 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001985-g003">Fig. 3D</xref>
###xml 318 325 306 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001985-g003">Fig. 3E</xref>
Thirdly, results from RT-PCR analyses showed that the level of IL-32 mRNA activated by poly(IC)+IFN-gamma was suppressed by COX-2-specific inhibitor NS398 in a dose dependent manner (Fig. 3D). Furthermore, IL-32 accumulation in culture supernatants stimulated by poly(IC)+IFN-gamma were suppressed by 80 microM NS398 (Fig. 3E).
###end p 56
###begin p 57
Taken together, these data suggest that COX-2 is an upstream regulatory factor of dsRNA-triggered IL-32 production.
###end p 57
###begin title 58
IL-32 feedback inhibits dsRNA-induced COX-2 expression
###end title 58
###begin p 59
###xml 298 305 298 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001985-g004">Fig. 4A</xref>
The effect of IL-32 on the regulation of COX-2 promoter was determined. A549 cells were cotransfected with the reporter plasmid pCOX-2-Luc and pCMV-Flag2A, Flag2A-IL-32. Results from Luciferase activity assay showed that the level of COX-2 promoter activity was decreased by IL-32 over-expression (Fig. 4A).
###end p 59
###begin title 60
The feedback inhibition of IL-32 to dsRNA-induced COX-2 expression.
###end title 60
###begin p 61
###xml 428 429 417 418 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 864 865 837 838 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Reporter plasmid pCOX-2-Luc (A) and pRL-TK were cotransfected along with Flag2A-IL-32 or control vectors (Flag2A) into A549 cells. Luciferase activity was then measured 48 h post transfection. A549 cells were transfected with different amounts of Flag2A-IL-32 as indicated or Flag2A and stimulated by poly(IC) (50 microg/ml)+IFN-gamma (150 U/ml) for 48 h. RT-PCR for COX-2 and beta-actin (B) in lysated cells, measurement of PGE2 release (C) in culture supernatants were taken. Reporter plasmid pCOX-2-Luc (D) and pRL-TK were cotransfected along with siRNA-IL-32 or siRNA-control into A549 cells and treated with poly(IC) (50 microg/ml)+IFN-gamma (150 U/ml) for 48 h. Luciferase activity was then measured. (E) A549 cells were transfected with siRNA-IL-32 or siRNA-control and stimulated by poly(IC) (50 microg/ml)+IFN-gamma (150 U/ml) for 48 h. Time-dependent PGE2 release in culture supernatants was measured. The data represent mean+/-s.d. of three separate experiments.
###end p 61
###begin p 62
###xml 81 82 81 82 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 443 450 433 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001985-g004">Fig. 4B</xref>
###xml 469 470 459 460 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 574 581 564 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001985-g004">Fig. 4C</xref>
To determine the effects of IL-32 on the regulation of COX-2 mRNA expression, PGE2 production, A549 cells were transfected with different amounts of Flag2A-IL-32 and treated with poly(IC)+IFN-gamma as the inducer. Results from RT-PCR using COX-2-specific, or beta-actin-specific primers showed that the levels of COX-2 mRNA was decreased as the amount of Flag2A-IL-32 increased, but the levels of beta-actin mRNA remained relatively constant (Fig. 4B). Furthermore, PGE2 production in culture supernatants was suppressed by IL-32 over-expression in a dose-dependent manner (Fig. 4C).
###end p 62
###begin p 63
###xml 287 294 283 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001985-g004">Fig. 4D</xref>
###xml 313 314 309 310 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 422 429 414 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001985-g004">Fig. 4E</xref>
To confirm the above results, IL-32-specific siRNA was cotransfected along with reporter plasmid pCOX-2-Luc into A549 cells and treated with poly(IC)+IFN-gamma. Results from Luciferase activity assay showed that the level of COX-2 promoter activity was increased by knocking down IL-32 (Fig. 4D). Furthermore, PGE2 production in culture supernatants stimulated with poly(IC)+IFN-gamma was enhanced by knocking down IL-32 (Fig. 4E).
###end p 63
###begin p 64
Taken together, these data suggest that IL-32 plays a very important role in the inflammatory response following an influenza A/COX-2/IL-32 dependent positive regulatory order, while a negative feedback to COX-2 biosynthesis was also first observed.
###end p 64
###begin title 65
###xml 23 24 23 24 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Influenza A-induced PGE2 production and IL-32 expression were inhibited by NS398 and Aspirin
###end title 65
###begin p 66
###xml 269 270 269 270 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 280 287 280 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001985-g005">Fig. 5A</xref>
###xml 300 307 300 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001985-g005">Fig. 5B</xref>
###xml 76 93 <span type="species:ncbi:11320">influenza A virus</span>
###xml 253 255 <span type="species:ncbi:11320">IV</span>
###xml 485 502 <span type="species:ncbi:11320">influenza A virus</span>
To confirm the COX-2 and IL-32 regulatory loop, A549 cells were infected by influenza A virus and treated with or without selective COX-2 inhibitor NS398, or non-selective COX inhibitor Aspirin, a widely used anti-inflammatory drug. Results showed that IV-triggered PGE2 release (Fig. 5A) and IL-32 (Fig. 5B) production in the culture supernatants were inhibited by either NS398 or Aspirin, which indicated that IL-32 is an important pro-inflammatory factor downstream of COX-2 during influenza A virus infection.
###end p 66
###begin title 67
###xml 106 123 <span type="species:ncbi:11320">influenza A virus</span>
Selective COX-2 inhibitor NS398 suppresses IL-32 expression and IL-32-specific siRNA upregulates COX-2 in influenza A virus infected A549 cell.
###end title 67
###begin p 68
###xml 161 162 157 158 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 356 357 352 353 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 28 45 <span type="species:ncbi:11320">influenza A virus</span>
###xml 317 334 <span type="species:ncbi:11320">influenza A virus</span>
A549 cells were infected by influenza A virus (1 MOI) and treated with or without 80 microM NS398, 5 mM Aspirin for 48 h as indicated on the horizontal axis. PGE2 release (A) and IL-32 production (B) in culture supernatants were measured. A549 cells were transfected with siRNA-IL-32 or siRNA-control and infected by influenza A virus (1 MOI) for 48 h. PGE2 release (C) and IL-32 production (D) in culture supernatants were measured. The data represent mean+/-s.d. of three separate experiments.
###end p 68
###begin title 69
###xml 23 24 23 24 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Influenza A-induced PGE2 production was increased by knocking down IL-32
###end title 69
###begin p 70
###xml 65 66 65 66 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 116 117 116 117 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 202 209 202 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001985-g005">Fig. 5C</xref>
###xml 243 250 243 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001985-g005">Fig. 5D</xref>
###xml 41 43 <span type="species:ncbi:11320">IV</span>
###xml 174 176 <span type="species:ncbi:11320">IV</span>
The effect of IL-32 on the regulation of IV infection induced PGE2 production was also determined. We found that PGE2 release in A549 cell culture supernatants stimulated by IV infection was increased (Fig. 5C) and IL-32 production decreased (Fig. 5D) by knocking down IL-32.
###end p 70
###begin p 71
###xml 167 173 167 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001985-g006">Fig. 6</xref>
###xml 88 105 <span type="species:ncbi:11320">influenza A virus</span>
Taken together, these data demonstrate that a novel inflammatory pathway in response to influenza A virus infection and dsRNA treatment was identified as described in Fig. 6.
###end p 71
###begin title 72
###xml 93 110 <span type="species:ncbi:11320">influenza A virus</span>
A model for regulation of pro-inflammatory factors COX-2 and IL-32 expression in response to influenza A virus infection and double-stranded RNA
###end title 72
###begin title 73
Discussion
###end title 73
###begin p 74
###xml 76 77 76 77 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 229 230 229 230 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 458 459 454 455 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 133 141 <span type="species:ncbi:9606">patients</span>
###xml 286 303 <span type="species:ncbi:11320">influenza A virus</span>
###xml 355 360 <span type="species:ncbi:9606">human</span>
Our results demonstrate that significant increase of serum COX-2-derived PGE2 and IL-32 levels were observed in influenza A infected patients compared with healthy individuals. Viral infection resulted in 2.7-fold increase in PGE2 synthesis and 58.2% increase in IL-32 production. Both influenza A virus infection and poly(IC)+IFN-gamma treatment in A549 human lung epithelial cells were able to induce COX-2/ IL-32 mRNA and protein expression as well as PGE2 and IL-32 accumulation in the cell culture supernatants. IL-32 was induced by influenza virus infection through COX-2-dependent mechanism.
###end p 74
###begin p 75
###xml 145 149 145 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Mizumura1">[26]</xref>
###xml 903 907 903 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Goodwin1">[31]</xref>
###xml 265 282 <span type="species:ncbi:11320">influenza A virus</span>
###xml 318 335 <span type="species:ncbi:11320">influenza A virus</span>
###xml 591 608 <span type="species:ncbi:11320">influenza A virus</span>
Although pro-inflammatory factor COX-2 has been identified as an obligatory mediator in the airway inflammation during influenza virus infection [26], virtually little is currently known regarding the regulation of a newly identified proinfammatory factor IL-32 in influenza A virus infection or the mechanism whereby influenza A virus upregulates IL-32 expression. The present study provides considerable new information relevant to these issues. We identified first a COX-2/IL-32 regulatory loop in which COX-2 upregulated IL-32 expression and IL-32 feedback inhibited COX-2 expression in influenza A virus infected A549 lung epithelial cells. At present, a possible "cross-talk" between two important pro-inflammatory factors nitric oxide synthase (NOS) and COX has been extensively examined in different cell lines, tissues and under different pathophysiological conditions with conflicting results [31]. But the relationship between COX-2 and IL-32 has not been evaluated.
###end p 75
###begin p 76
###xml 14 16 <span type="species:ncbi:11320">IV</span>
###xml 76 81 <span type="species:ncbi:9606">human</span>
###xml 201 206 <span type="species:ncbi:9606">human</span>
Comparing the IV infection induced IL-32 level in cell culture with that in human individuals, a significant difference between them was observed, over 10-fold increase in cell culture versus 58.2% in human individuals. It is likely the pro-inflammatory factor is not able to be increased sharply under physiological conditions due to complex inflammation network in which pro-inflammatory factors regulate each other.
###end p 76
###begin p 77
###xml 105 107 <span type="species:ncbi:11320">IV</span>
###xml 273 290 <span type="species:ncbi:11320">influenza A virus</span>
Two viral components, the NS1 and viral replicative intermediate dsRNA were identified to be involved in IV infection triggered COX-2 and IL-32 expression in A549 cells. Because TLR3 contributes directly to the inflammatory response of respiratory epithelial cells to both influenza A virus and dsRNA, we focused on the function of dsRNA in the regulation of COX-2 and IL-32 expression in this study. Role of viral NS1 protein in the pro-inflammatory process need further investigation.
###end p 77
###begin p 78
###xml 84 88 84 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Samuelsson1">[32]</xref>
###xml 159 163 159 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Vane1">[33]</xref>
###xml 182 186 182 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Subbaramaiah1">[34]</xref>
###xml 188 192 188 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Kutchera1">[35]</xref>
###xml 441 445 441 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-White1">[36]</xref>
###xml 447 451 447 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Naesdal1">[37]</xref>
###xml 453 457 453 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Coruzzi1">[38]</xref>
###xml 600 604 600 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Wu1">[39]</xref>
###xml 971 975 971 975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0001985-Coruzzi1">[38]</xref>
Cyclooxygenase metabolizes arachidonic acid to prostaglandins (PGs) and thromboxane [32]. COX-2 has been elucidated to be crucial to the inflammatory response [33] and tumorigenesis [34], [35], so nonsteroidal anti-inflammatory drugs (NSAIDs) selective for its inhibition are used clinically to treat inflammatory arthropathies but always cause many side effects such as gastrointestinal (GI) mucosa damage and cardiovascular adverse events [36], [37], [38]. Aspirin is one of the classic NSAIDs, and its anti-inflammatory activity is associated with cyclooxygenase inhibition directly or indirectly [39]. NSAID-associated GI mucosal injury is an important clinical problem and the increased knowledge of physiological roles of COX-2 enzyme in a variety of tissues, including stomach and kidney, together with the withdrawal from the clinic trials of rofecoxib and valdecoxib because of cardiovascular toxicity, have challenged the benefits of selective COX-2 inhibition [38]. Our study identified a novel COX-2 downstream pro-inflammatory factor IL-32 which could be a potential target for screening anti-inflammatory drugs with less adverse effects.
###end p 78
###begin p 79
###xml 82 88 82 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0001985-g006">Fig. 6</xref>
###xml 217 218 213 214 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 98 115 <span type="species:ncbi:11320">influenza A virus</span>
In summary, these studies provide new insights into a novel model as described in Fig. 6 in which influenza A virus or poly(IC)+IFN-gamma triggers pro-inflammatory factors COX-2 and IL-32 expression, COX-2-derived PGE2 production, and subsequent host inflammatory responses. In this model, we further demonstrate that COX-2 is located up-stream of IL-32 in the positive regulatory pathway. The cross-talk between the two genes is described as follows: COX-2 upregulates IL-32 production, and conversely, IL-32 attenuates COX-2 activity.
###end p 79
###begin p 80
We thank Hubei provincial Center for Disease Control and Prevention (Hubei CDC) for providing serum samples with seronegative for influenza A antigen in this study, and thank Dr. Kenneth K. Wu for kindly providing plasmid pcDNA3.1-COX-2.
###end p 80
###begin title 81
References
###end title 81
###begin article-title 82
###xml 100 106 <span type="species:ncbi:10090">murine</span>
Double-stranded RNA-induced inducible nitric-oxide synthase expression and interleukin-1 release by murine macrophages requires NF-kappaB activation.
###end article-title 82
###begin article-title 83
When two strands are better than one: the mediators and modulators of the cellular responses to double-stranded RNA.
###end article-title 83
###begin article-title 84
###xml 111 128 <span type="species:ncbi:11320">influenza A virus</span>
Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus.
###end article-title 84
###begin article-title 85
Diesel exhaust enhances virus- and poly(I:C)-induced Toll-like receptor 3 expression and signaling in respiratory epithelial cells.
###end article-title 85
###begin article-title 86
###xml 59 85 <span type="species:ncbi:12104">encephalomyocarditis virus</span>
Role of MAPK in the regulation of double-stranded RNA- and encephalomyocarditis virus-induced cyclooxygenase-2 expression by macrophages.
###end article-title 86
###begin article-title 87
Regulation of cyclooxygenase-2 expression by macrophages in response to double-stranded RNA and viral infection.
###end article-title 87
###begin article-title 88
Intratracheal double-stranded RNA plus interferon-gamma: a model for analysis of the acute phase response to respiratory viral infections.
###end article-title 88
###begin article-title 89
###xml 66 84 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production.
###end article-title 89
###begin article-title 90
Potential role of PKR in double-stranded RNA-induced macrophage activation.
###end article-title 90
###begin article-title 91
###xml 22 27 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes. A hit and run phenomenon.
###end article-title 91
###begin article-title 92
Cyclooxygenase-2-10 years later.
###end article-title 92
###begin article-title 93
Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition.
###end article-title 93
###begin article-title 94
Up-regulation of p300 binding and p50 acetylation in tumor necrosis factor-alpha-induced cyclooxygenase-2 promoter activation.
###end article-title 94
###begin article-title 95
###xml 129 134 <span type="species:ncbi:9606">human</span>
An essential role of the nuclear factor of activated T cells in the regulation of the expression of the cyclooxygenase-2 gene in human T lymphocytes.
###end article-title 95
###begin article-title 96
Spike protein of SARS-CoV stimulates cyclooxygenase-2 expression via both calcium-dependent and calcium-independent protein kinase C pathways.
###end article-title 96
###begin article-title 97
Nucleocapsid protein of SARS-CoV activates the expression of cyclooxygenase-2 by binding directly to regulatory elements for nuclear factor-kappa B and CCAAT/enhancer binding protein.
###end article-title 97
###begin article-title 98
Contrasting effects of cyclooxygenase-1 (COX-1) and COX-2 deficiency on the host response to influenza A viral infection.
###end article-title 98
###begin article-title 99
###xml 47 52 <span type="species:ncbi:9606">human</span>
COX-2 expression and cell cycle progression in human fibroblasts.
###end article-title 99
###begin article-title 100
Interleukin-32: a cytokine and inducer of TNFalpha.
###end article-title 100
###begin article-title 101
IL-32: an emerging player in the immune response network against tuberculosis?
###end article-title 101
###begin article-title 102
IL-32, a proinflammatory cytokine in rheumatoid arthritis.
###end article-title 102
###begin article-title 103
###xml 0 26 <span type="species:ncbi:1773">Mycobacterium tuberculosis</span>
Mycobacterium tuberculosis induces interleukin-32 production through a caspase- 1/IL-18/interferon-gamma-dependent mechanism.
###end article-title 103
###begin article-title 104
IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism.
###end article-title 104
###begin article-title 105
Proteinase 3 is an IL-32 binding protein.
###end article-title 105
###begin article-title 106
###xml 4 21 <span type="species:ncbi:10407">hepatitis B virus</span>
The hepatitis B virus X protein promotes tumor cell invasion by inducing membrane-type matrix metalloproteinase-1 and cyclooxygenase-2 expression.
###end article-title 106
###begin article-title 107
Role of mitogen-activated protein kinases in influenza virus induction of prostaglandin E2 from arachidonic acid in bronchial epithelial cells.
###end article-title 107
###begin article-title 108
Dynamic regulation of cyclooxygenase-2 promoter activity by isoforms of CCAAT/enhancer-binding proteins.
###end article-title 108
###begin article-title 109
Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases.
###end article-title 109
###begin article-title 110
Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase.
###end article-title 110
###begin article-title 111
###xml 14 31 <span type="species:ncbi:11320">Influenza A virus</span>
###xml 113 118 <span type="species:ncbi:9606">human</span>
Cutting Edge: Influenza A virus activates TLR3-dependent inflammatory and RIG-I-dependent antiviral responses in human lung epithelial cells.
###end article-title 111
###begin article-title 112
Effects of nitric oxide and nitric oxide-derived species on prostaglandin endoperoxide synthase and prostaglandin biosynthesis.
###end article-title 112
###begin article-title 113
An elucidation of the arachidonic acid cascade. Discovery of prostaglandins, thromboxane and leukotrienes.
###end article-title 113
###begin article-title 114
Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation.
###end article-title 114
###begin article-title 115
Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells.
###end article-title 115
###begin article-title 116
###xml 54 59 <span type="species:ncbi:9606">human</span>
Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect.
###end article-title 116
###begin article-title 117
Cardiovascular effects of the selective cyclooxygenase-2 inhibitors.
###end article-title 117
###begin article-title 118
NSAID-associated adverse effects and acid control aids to prevent them: a review of current treatment options.
###end article-title 118
###begin article-title 119
Gastrointestinal safety of novel nonsteroidal antiinflammatory drugs: selective COX-2 inhibitors and beyond.
###end article-title 119
###begin article-title 120
Aspirin and other cyclooxygenase inhibitors: new therapeutic insights.
###end article-title 120
###begin p 121
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 121
###begin p 122
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by research grants from the National Natural Science Foundation of China (No. 30570066), the Major State Basic Research Development Program of China ("973" project No. 2007CB512803 and No. 2005CB523010), the National High-Tech Research and Development Program of China ("863" project No. 2006AA02A306), Hubei Provincial Science Foundation for Distinguished Youth Scholar to Zhu Y, and the Ph.D. Program Foundation of Ministry of Education of China (No. 20050486012). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 122

